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Introduction to OARSI FDA initiative OAC special editionSince July 1999, the Food and Drug Administration (FDA) has
provided guidance for industry on “Clinical Development
Programs for Drugs, Devices, and Biological Products Intended
for the Treatment of Osteoarthritis (OA)”1. This draft guidance
document was intended to assist sponsors who were developing
drugs, devices or biological products for OA and included
a number of issues for sponsor consideration including the utility
of animal models and the measurement of improvement in OA.
The draft guidance discussed the types of label claims that could
be considered for OA products and provided guidance on the clin-
ical development programs to support these claims. It was recog-
nized that OA is a disease with a complex pathophysiology and
thus, multiple clinical outcomes for product claims could be
considered such as an improvement in signs and symptoms or
a delay in structural progression. Additionally, the 1999 draft
guidance also proposed, in principal, a claim for prevention of
OA. The FDA solicited comments to the draft document and until
2007 no further update was published. It should be noted that
under this draft guidance, no products have been approved in
the US for the indications of either delay in structural progression
or prevention of OA.
On August 14, 2007, a request for proposals (RFP) was posted by
the FDA in the Federal Register seeking an updated critical appraisal
on the issues related to clinical development programs for the
treatment and prevention of OA that would help inform their
internal discussions and subsequent ﬁnalization of the 1999 OA
draft guidance2.
In response to this solicitation, the Osteoarthritis Research
Society International (OARSI) submitted a proposal outlining
a speciﬁc approach to the management and coordination of a crit-
ical appraisal of the science related to the design of clinical devel-
opment programs for the treatment and prevention of OA. In
June 2008, OARSI received approval from the FDA to embark on
an 18-month review of the current literature resulting in a series
of recommendations for the FDA’s consideration as they embark
upon ﬁnalizing the 1999 OA draft guidance.
Under the direction of an executive committee and through
a series of individual committee meetings and teleconferences
as well as two open public meetings, eight working groups
comprised of individuals from academia, professional societies,
industry and governmental agencies [Appendix 1] addressed
speciﬁc questions outlined within the FDA’s original notice.
The result was a comprehensive report encompassing the
recommendations by each working group based on the current
state of knowledge on the pre-deﬁned topics outlined with the
original notice as well as a series of on-going research recom-
mendations to further inform the evolving areas of structural1063-4584/$ – see front matter  2011 Published by Elsevier Ltd on behalf of Osteoarth
doi:10.1016/j.joca.2010.12.013change and the role of biomarkers in the context of clinical
trials.
This special edition of Osteoarthritis and Cartilage provides an
insightful, evidence based exploration and discussion on impor-
tant issues related to current and future OA clinical program
development. While much has been learned since 1999, OA still
remains a disease characterized by a prolonged pre-radiographic
phase followed by evident structural joint changes, associated
with frequent pain and loss of function. The research discussed
herein recognizes how far we have come and charts the course
for future research into the development of new therapies and
devices for OA, as well as the potential for disease modifying
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